ClinicalTrials.gg
WithdrawnNCT04020653Updated Mar 3, 2020

A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria

A Phase 2 interventional study of 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD and Sodium ferrous citrate (SFC) 472 mg QD in Malaria, sponsored by Neopharma Japan Co., Ltd.. Withdrawn. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-03-03.

Sponsored by Neopharma Japan Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Considering the Thai FDA requirement, changes of Malaria cases in Thailand and EC recommendation, the decision to withdrawal the study was made.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a pilot, double-blind, randomized, parallel-group, placebo-control, exploratory study to evaluate the efficacy and safety of 5-aminolevulinic acid hydrochloride (5-ALA HCl) and sodium ferrous citrate (SFC) added on artemisinin-based combination therapy (ACT) compared with ACT alone in the treatment of malaria. Patients who are suffering from uncomplicated malaria, are eligible for randomization.The study will be conducted in a total of 75 patients with uncomplicated malaria.

Read the detailed description

Approximately 75 patients will be randomized in a 1:2:2 ratio to 3 arms:

Arm 1: placebo+ACT group (15 patients)

Arm 2: 5 ALA/SFC+Placebo+ACT twice daily (BID) (30 patients)

Arm 3: 5-ALA/SFC+Placebo+ACT once daily (QD) (30 patients)

The study duration will be a maximum of 98 days with treatment period of 7 days and follow-up period of 91 days.

02

Conditions studied

  • Malaria

Browse trials for

Keywords

  • Uncomplicated malaria
  • sodium ferrous citrate (SFC)
  • 5-aminolevulinic acid hydrochloride (5-ALA HCl)
  • artemisinin-based combination therapy
03

In context

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Lead sponsor

This is the only study on the registry with Neopharma Japan Co., Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients of 18 to 60 years inclusive.
  2. Weighing 35 to 90 kg.
  3. Women with child bearing potential willing to give consent for pregnancy test.
  4. Presence of symptomatic uncomplicated malaria of all species inclusive with a diagnosis confirmed by:

    A. Microscopically confirmed parasite infection, between 500 and 100,000 asexual parasite count/μL of blood.

    B. Fever, as defined by axillary/tympanic of ≥37.5°C within 24 hours before randomization (must be documented).

  5. Patients must be willing and able to give written and comply with all study visits and procedures. If a patient cannot read informed consent and/or write a signature, an impartial witness who speaks the language of the patient must be present during the entire informed consent process and discussion with the patient.

Exclusion criteria

Exclusion Criteria:

  1. Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization (WHO) Criteria 2010.
  2. Severe vomiting, defined as more than three times in the 24 hours prior to inclusion in the study or inability to tolerate oral treatment.
  3. Known history of photo-, porphyria, or hemochromatosis.
  4. Have taken any medication with antimalarial or antibiotic with antimalarial effect within 14 days before randomization.
  5. Received an drug within the past 28 days.
  6. Patients whose (Hb) level is lower than 8 g/dL.
  7. Liver function tests (/alanine aminotransferase [AST/ALT] levels) more than 2.5 times values.
  8. Known (HIV) or virus (HCV) or surface antigen (HBsAg) positive, testing is not required.
  9. Known significant renal impairment as indicated by serum creatinine of ≥1.4 mg/dL or estimated (eGFR) of \<45 mL/min.
  10. Known history of hypersensitivity, allergic or adverse reactions to 5-aminolevulinic acid and sodium ferrous citrate.
  11. Presence or history of uncontrolled systemic disease.
  12. Female patients who are pregnant or breast-feeding.
  13. Any other condition in the opinion of the investigator makes the patient unsuitable for study
  14. Received any medication specified as for ACT or affecting blood concentration of ACT within 5 times the half-life of each medication before the first dose of study medication.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Placebo + ACT

    Patients will receive placebo for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.

    Drug: Artemisinin-based combination (ACT) · Drug: Placebo

  • Experimental
    5 ALA/SFC+placebo+ACT BID

    5-ALA HCl 300 mg and SFC 236 mg will be administered BID for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3. Patients will receive 5-ALA HCl+Placebo and SFC+Placebo at odd number of study medication dosing (Dose 1, 3, 5, 7, 9, 11, 13) and only 5-ALA HCl and SFC at even numbers of study medication dosing (Dose 2, 4, 6, 8, 10,12, 14).

    Drug: Artemisinin-based combination (ACT) · Drug: Placebo · Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID · Drug: Sodium ferrous citrate (SFC) 236 mg BID

  • Experimental
    5-ALA/SFC+placebo+ACT QD

    5-ALA HCl 600 mg and SFC 472 mg will be administered QD in the morning or evening for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3. Patients will receive 5-ALA HCl and SFC at odd number of study medication dosing (Dose 1, 3, 5, 7) and placebo at even numbers of study medication dosing (Dose 2, 4, 6).

    Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD · Drug: Sodium ferrous citrate (SFC) 472 mg QD · Drug: Artemisinin-based combination (ACT) · Drug: Placebo

Interventions

  • 5-ALA HCl 150 mg capsules will be given to the patients as 600 mg QD

  • DrugSodium ferrous citrate (SFC) 472 mg QD

    SFC 118 mg capsules will be given to the patients as 472 mg QD

  • DrugArtemisinin-based combination (ACT)

    Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT. ACT will be supplied as a combination tablet.

    Also known as: Artemether 20 mg and lumefantrine 120 mg

  • DrugPlacebo

    Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients

  • 5-ALA HCl 150 mg capsules will be given to the patients as 300 mg BID

  • DrugSodium ferrous citrate (SFC) 236 mg BID

    SFC 118 mg capsules will be given to the patients as 236 mg BID

06

What researchers measure

Primary outcomes

  1. Number of patients with adverse events

    Number of patients with any adverse events or clinically significant abnormal laboratory parameters to investigate safety and tolerability of 5-ALA HCl and SFC in simultaneous administration with ACT.

    Time frame: From screening visit (Day -1) untill the Follow-up Visit (Day 98)

  2. Cure rate on Day 28

    Cure rate is defined as the proportion of patients with polymerase chain reaction (PCR)-corrected Adequate Clinical and Parasitological Response (ACPR). PCR-corrected ACPR is defined as patients with clearance of asexual parasites within 28 days of initiation of study medication and without recrudescence within 28 days. Cure rate to investigate the preliminary efficacy of 5-ALA HCl and SFC in simultaneous administration with ACT.

    Time frame: Day 28

  3. Parasite Clearance Time

    Time from first dosing to time of first of 4 consecutive readings with zero parasite count in blood. Calculated based on parasite count in blood every 4 hours after the start of study medication for 72 hours until there are 4 consecutive negative readings.

    Time frame: Every 4 hours for 72 hours from Day 1 to Day 7 until 4 consecutive negative readings

  4. Fever Reduction Time

    Time to Fever Reduction is defined as the time from first dosing to first normal reading of temperature (\<37.5 °C) for two consecutive normal temperature reading plus confirmed normal temperature every 4 hours after the start of study medication for 72 hours

    Time frame: Every 4 hours for 72 hours from Day 1 to Day 7

  5. Gametocyte Clearance Time

    Time from the first dose until first total and continued disappearance of gametocytes which remains at least a further 24 hours

    Time frame: Day 1 to Day 7 + 24 hours

  6. Change in inflammatory parameter: C-reactive protein

    Change from baseline in C-reactive protein to investigate change in inflammatory parameters

    Time frame: Days 1, 3, 7, and 28

  7. Change in inflammatory parameter: interleukin-6

    Change from baseline in interleukin-6 to investigate change in inflammatory parameters

    Time frame: Days 1, 3, 7, and 28

  8. Change in inflammatory parameter: tumor necrosis factor (TNF)-alpha

    Change from baseline in tumor necrosis factor (TNF)-alpha to investigate change in inflammatory parameters

    Time frame: Days 1, 3, 7, and 28

  9. Change in iron metabolism: Serum iron

    Change from baseline in serum iron to investigate change in iron metabolism parameters

    Time frame: Days 1, 3, 7, 28, and 98

  10. Change in iron metabolism: Hepcidin

    Change from baseline in hepcidin to investigate change in iron metabolism parameters

    Time frame: Days 1, 3, 7, 28, and 98

  11. Change in iron metabolism: total iron binding capacity (TIBC)

    Change from baseline in total iron binding capacity (TIBC) to investigate change in iron metabolism parameters

    Time frame: Days 1, 3, 7, 28, and 98

  12. Change in iron metabolism: unsaturated iron binding capacity (UIBC)

    Change from baseline in unsaturated iron binding capacity (UIBC) to investigate change in iron metabolism parameters

    Time frame: Days 1, 3, 7, 28, and 98

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2019; primary completion for May 2020, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2019
First posted
Jul 16, 2019
StartEst.
Sep 6, 2019
Primary completionEst.
May 31, 2020
CompletionEst.
Sep 30, 2020
Last update
Mar 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04020653
Lead sponsor
Neopharma Japan Co., Ltd.
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jul 16, 2019
Start date
Sep 6, 2019 (estimated)
Primary completion
May 31, 2020 (estimated)
Completion
Sep 30, 2020 (estimated)
Last update
Mar 3, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aminolevulinic Acid

Start the discussion